Google
XERS — XERIS PHARMACEUTICALS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
XERS FAQ
What is XERS's P/E ratio?
XERIS PHARMACEUTICALS INC (XERS) currently trades at a P/E ratio of 74.33.
What is XERS's ROE?
XERIS PHARMACEUTICALS INC reports a Return on Equity (ROE) of 92.29%.
What is XERS's dividend yield?
XERIS PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is XERS's Deepscope Quality Score?
Deepscope rates XERS's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XERS?
Deepscope's AI Timing Score for XERS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XERS belong to?
XERIS PHARMACEUTICALS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 6.15
Price
0.26
(4.41%)
Day Change
|
|
|---|
XERS, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
P/E ratio is relatively high
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
3096
|
| Magic Formula Rank by ROE |
3096
|
| Magic Formula Rank by ROIC |
3109
|
| Price | 6.15 |
| PBV / Sector |
79.61 / 2.65
|
| Earning Per Share | 0.07 |
| PE / Sector |
74.33 / 22.84
|
| PEG or PE/Growth / Sector |
-1.45 / 0.11
|
| Average 1M Daily Value |
10.79 M
GREAT
|
| Average 1W Daily Value |
9.05 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:01 |
| Symbol | XERS |
| Name | XERIS PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 172.64 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,035.85 / 9,638.91 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1375 West Fulton Street, Chicago, IL, United States, 60607
Phone: 844 445 5704
Website: https://www.xerispharma.com
Employees: 435
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
